The Incretin System and Cardiovascular Risk: Effects of Incretin-Targeted Therapies
- نوع فایل : کتاب
- زبان : انگلیسی
- مؤلف : Dhanwantee Mundil & M. Hossein Noyan-Ashraf & Mansoor Husain
- چاپ و سال / کشور: 2010
Description
Incretins, such as glucagon-like peptide-1 (GLP-1), are gut peptides that stimulate insulin secretion. Incretintargeted therapeutics for type 2 diabetes include both direct GLP-1 receptor (GLP-1R) agonists and indirect dipeptidyl peptidase-4 (DPP-4) inhibitors, which inhibit the degradation of native GLP-1. Evidence from basic mechanistic studies in animal models of cardiovascular disease and emerging evidence from pooled analyses of clinical trials suggest beneficial cardiovascular effects of these drugs in addition to their ability to reduce hyperglycemia. This article reviews the actions of incretin-based drugs on blood pressure, vasomotor function, myocardial ischemia, and other cardiovascular risk factors and proposes additional avenues of research.
Curr Cardiovasc Risk Rep (2011) 5:62–69 DOI 10.1007/s12170-010-0141-5 Published online: 10 November 2010
